Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 387

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 4
Chunk 387
---
 Units to
cover over-allotments, if any. Simultaneously with the closing of the IPO, we consummated the private placement with Drugs Made In America
Acquisition LLC, our sponsor, of 400,000 Private Placement Units at a price of $10.00 per unit, for $4,000,000.

On February 13, 2025, the underwriters
exercised the over-allotment option in full, and the closing of the issuance and sale of the Over-Allotment Option Units occurred on February
18, 2025. The total aggregate issuance by us of 3,000,000 Over-Allotment Option Units at a price of $10.00 per unit resulted in total
gross proceeds of $30,000,000. On February 18, 2025, simultaneously with the sale of the Over-Allotment Option Units, we consummated the
private sale of an additional 30,000 Private Placement Units, generating gross proceeds of $300,000.

12

As of February 18, 2025, a total
of $ 231,150,000 of the net proceeds from the sale of Units in the IPO (including the Over-Allotment Option Units) and the private placement
of the Private Placement Units, were placed in a trust account established for the benefit of the Company’s public shareholders.
The funds in the trust account will be invested only in U.S. government treasury obligations with a maturity of 185 days or less or in
money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government
treasury obligations and/or held as cash or cash items (including in demand deposit accounts).

For a description of the use
of the proceeds generated in our IPO and the private placement of the Private Placement Units, see Part II, Item 7 (Management’s
Discussion and Analysis of Financial Condition and Results of Operations) of this Annual Report on Form 10-K. There has been no material
change in the planned use of proceeds from the IPO and the private placement of the Private Placement Units as described in the Registration
Statement. The specific investments in our trust account may change from time to time.

Purchases of Equity Securities by the Issuer
and Affiliated Purchasers

None.

ITEM 6. [RESERVED]

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION